Pharmaceutical companies are suddenly trading entire divisions the way sports teams swap players. Glaxo, Novartis and Ely Lily are all involved in a complicated deal announced Tuesday, and so far this year, five deals exceeding $2 billion have been announced. What’s driving the deal-making?
